LeMaitre upgraded to Outperform from Market Perform at Barrington

Barrington analyst Michael Petusky upgraded LeMaitre Vascular to Outperform with a $34 price target. Friday’s 21% on the disappointing preliminary Q3 results was overdone and provides investors with an attractive entry point, Petusky tells investors in a research note. He believes the shares are “no longer priced for perfection.”
https://thefly.com/landingPageNews.php?id=2800893